WT3 dosing

[Guest guest]

Heidi,

You wrote:

> Is there information (books or web) about this protocol? I'd like to

> read more.

IIRC, I first ran across this approach bemoaning the use (or abuse) of

T3 for competitive weight lifting. However, it is also evidently part of

's treatment for subclinical hypoT, something again rather

controversial.

Here's a blurb on it:

P R Health Sci J. 2006 Mar;25(1):23-9.

Supraphysiological cyclic dosing of sustained release T3 in order to

reset low basal body temperature.

Friedman M, Miranda-Massari JR, MJ.

Friedman Clinic, Montpelier, VT, USA.

The use of sustained release tri-iodothyronine (SR-T3) in clinical

practice, has gained popularity in the complementary and alternative

medical community in the treatment of chronic fatigue with a protocol

(WT3) pioneered by Dr. Denis . The WT3 protocol involves the use

of SR-T3 taken orally by the patient every 12 hours according to a

cyclic dose schedule determined by patient response. The patient is then

weaned once a body temperature of 98.6 degrees F has been maintained for

3 consecutive weeks. The symptoms associated with this protocol have

been given the name 's Temperature Syndrome (WTS). There have been

clinical studies using T3 in patients who are euthyroid based on normal

TSH values. However, this treatment has created a controversy in the

conventional medical community, especially with the American Thyroid

Association, because it is not based on a measured deficiency of thyroid

hormone. However, just as estrogen and progesterone are prescribed to

regulate menstrual cycles in patients who have normal serum hormone

levels, the WT3 therapy can be used to regulate metabolism despite

normal serum thyroid hormone levels. SR-T3 prescription is based

exclusively on low body temperature and presentation of symptoms.

Decreased T3 function exerts widespread effects throughout the body. It

can decrease serotonin and growth hormone levels and increase the number

of adrenal hormone receptor sites. These effects may explain some of the

symptoms observed in WTS. The dysregulation of neuroendocrine function

may begin to explain such symptoms as alpha intrusion into slow wave

sleep, decrease in blood flow to the brain, alterations in carbohydrate

metabolism, fatigue, myalgia and arthralgia, depression and cognitive

dysfunction. Despite all thermoregulatory control mechanisms of the body

and the complex metabolic processes involved, WT3 therapy seems a

valuable tool to re-establish normal body functions. We report the

results of 11 patients who underwent the WT3 protocol for the treatment

of CFS. All the patients improved in the five symptoms measured. All

patients increased their basal temperature. The recovery time varied

from 3 weeks to 12 months.

Chuck